Drug search by name

Lorcaserin Extended-Release Tablets and Depression

Result of checking the interaction of drug Lorcaserin Extended-Release Tablets and disease Depression for safety when used together.

Check result:

Lorcaserin Extended-Release Tablets <> Depression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Drugs like lorcaserin that target the central nervous system have been associated with depression and suicidal ideation. Psychiatric events of euphoria, hallucination, and dissociation were observed with lorcaserin at supratherapeutic dosages in short-term studies. In clinical trials of at least one year duration, 0.2% of patients treated with lorcaserin developed euphoria, compared to <0.1% treated with placebo. Therapy with lorcaserin should be administered cautiously in patients with preexisting depression or psychiatric illnesses. Lorcaserin dosage should not exceed 10 mg twice a day, and patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Lorcaserin should be discontinued in patients who experience suicidal thoughts or behavior.

Lorcaserin Extended-Release Tablets

Generic Name: lorcaserin

Brand Name: Belviq, Belviq XR

Synonyms: Lorcaserin

What is Lorcaserin Extended-Release Tablets?